الأحد 13 محرم 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| OPEN LABEL, RANDOMIZED, SINGLE SITE CLINICAL TRIAL TO COMPARE THE SAFETY & EFFICACY OF HERBAL MELANIN EXTRACTED FROM NIGELLA SATIVA SEEDS VS STANDARD OF CARE TREATMENT IN TREATING GASTRITIS PATIENTS | KAIMRC | Rejected | Melanole NIGELLA SATIVA | 2 | RC15/152/R | N/A |
| ATOS study_A 12–month prospective observational study assessing the real-world clinical effectiveness, safety and health-economic benefits of Toujeo® initiation after oral antidiabetic drug failure in insulin-naïve patients with type 2 diabetes mellitus | SANOFI | Ongoing | TOUJEO | 4 | OBS14708 | King Abdulaziz University Hospital (Jeddah), Dr. Ghassan N. Pharaon General Hospital (Jeddah), Dallah Hospital (Riyadh), Alzafer Hospital (Najran), Dr. Bakhsh Hospital (Jeddah), Saudi German Hospital (Jeddah), Arrawdha General Hospital (Dammam), Almana Hospital (Jubail), Almouwasat Hospital (Dammam), Specialized Medical Center (Riyadh) |
| "A 12-week, multicenter, randomized, double-blind, placebo-controlledstudy to assess the efficacy and safety of QAW039 when added tostandard-of-care asthma therapy in patients with uncontrolled asthma" | Novartis | Ongoing | QAW039/Fevipiprant | 3 | CQAW039A2316 | King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| "A 2-treatment period, randomized, placebo-controlled,multicenter parallel-group study to assess the safety ofQAW039 when added to existing asthma therapy in GINAsteps 3, 4 and 5 patients with uncontrolled asthma" | Novartis | Ongoing | QAW039/Fevipiprant | 3 | CQAW039A2315 | King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions. | MEDIS Laboratories | Ongoing | Tacrolimus/ Prograf | BE | 19-2017 | Saudi Ajal |
| "A PHASE III, MULTICENTER,RANDOMISED, DOUBLEBLIND,PLACEBOCONTROLLEDSTUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER" | Roche | Ongoing | ATEZOLIZUMAB / PACLITAXEL | 3 | MO39196 | International Medical Center (Jeddah), King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh) |
| A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer | Eli Lilly | Ongoing | abemaciclib | 3 | I3Y-MC-JPCF | King Fahad Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam) |
| "A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack[THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death]" | AstraZeneca | Ongoing | Ticagrelor | 3 | D5134C00003 | King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders | Bellicum Pharmaceuticals | Ongoing | Rimiducid | 2 | CT17-008-R | King Abdulaziz Medical City NG (Riyadh) |
| A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors | Novartis | Ongoing | ABL001 | 3 | CABL001A2301 | King Faisal Specialist Hospital and Research Center (Riyadh) |
تاريخ آخر تحديث: 08/05/2025 بتمام الساعة 03:17 مساء بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.